JAK2 and acute myeloid leukemia: JAK2 hyperactivating mutations occur in AML [40], and a study by Ikezoe et al. demonstrated that p-JAK2 elevation in AML bone marrow samples was correlated with unsatisfactory clinical outcomes [41].